T-Therapeutics is focused on harnessing the natural capabilities of T cells to develop innovative cancer therapies. The company utilizes its proprietary OpTiMus® platform, which is a highly engineered transgenic mouse model designed to produce fully human T cell receptors (TCRs) that are not found in the human immune repertoire. This platform allows T-Therapeutics to generate a vast array of unique TCRs with specific properties, enabling the development of targeted therapies that can effectively recognize and attack cancer cells. By employing advanced techniques such as machine learning and single-cell genomics, the company aims to identify optimal TCRs that can serve as foundational elements for next-generation cancer treatments.

In addition to its TCR-based therapies, T-Therapeutics is also developing T-Bridge® molecules, which are precision medicines tailored to target specific cancers and inflammatory conditions based on individual genetic profiles. These molecules leverage personalized molecular data to enhance treatment efficacy, ensuring that therapies are finely tuned to the unique characteristics of both the disease and the patient. By focusing on the molecular makeup of cancer cells and the patient's genetic information, T-Therapeutics is committed to advancing precision medicine, ultimately reshaping the clinical landscape for patients with currently untreatable cancers and other diseases.

United Kingdom

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs.

We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.

T-Therapeutics

Company Details